In Vitro Diagnostics Medical Device Market: Supplier Concentration, Reimbursement Risk, and the Hospital-Dominated Buying Pattern
Core keywords: in vitro diagnostics, supplier concentration, immuno diagnostics, hospital procurement, regulatory compliance

The global in vitro diagnostics medical device market presents a paradox for procurement leaders and investment analysts. The top five manufacturers—Roche, Danaher, Abbott, Siemens Healthineers, and Thermo Fisher Scientific—hold approximately 51.0% of revenue, a concentration that would suggest supplier leverage is heavily skewed toward vendors. Yet the market’s growth trajectory is shaped by forces that fragment buying power rather than concentrate it: hospital applications account for 57.6% of demand, but procurement decisions within hospitals are distributed across laboratory directors, infection control committees, and value analysis teams. Immuno diagnostics leads product segments at 26.4%, but the category spans automated chemistry analyzers, point-of-care cartridges, and molecular platforms with radically different qualification requirements. And the regulatory environment—fragmented across FDA, CE marking, NMPA, and dozens of national regimes—creates compliance costs that vary by jurisdiction and therapeutic area. This analysis examines what that structure means for sourcing strategy, reimbursement exposure, and the qualification burden that determines whether a lower-cost alternative is actually a lower-cost decision.

Definition and the Procurement Relevance of IVD Classification
In Vitro Diagnostic tests are a subset of medical devices. In vitro diagnostic products are those reagents, instruments, and systems intended for use in diagnosis of disease or other conditions, including a determination of the state of health, in order to cure, mitigate, treat, or prevent disease or its sequelae. Such products are intended for use in the collection, preparation, and examination of specimens taken from the human body. In vitro diagnostics are tests that can detect diseases, conditions, or infections. Some tests are used in laboratory or other health professional settings and other tests are for consumers to use at home. A medical device is an in vitro diagnostic medical device if it is a reagent, calibrator, control material, kit, specimen receptacle, software, instrument, apparatus, equipment or system, whether used alone or in combination with other diagnostic goods for in vitro use.

For technical decision-makers, the classification matters because it determines the regulatory pathway and, by extension, the qualification timeline. A Class II immunoassay analyzer cleared through the FDA’s 510(k) process requires different evidence than a Class III companion diagnostic requiring premarket approval. In the European Union, the IVDR transition has imposed stricter clinical evidence requirements on a category of tests that previously operated under less demanding oversight. The procurement implication is that “IVD” is not a homogeneous sourcing category. A buyer evaluating a chemistry analyzer for a hospital core lab faces a different qualification burden than a buyer evaluating a point-of-care molecular platform for an emergency department.

Market Drivers: Early Diagnosis, Personalized Medicine, and the Pandemic Legacy
The IVD medical device market is driven by several key factors, starting with the growing demand for early diagnosis and personalized medicine. As healthcare systems focus more on preventative care and precise treatment plans, IVDs play a crucial role in detecting diseases at an early stage and tailoring therapies accordingly. Additionally, advancements in technology, such as point-of-care testing, molecular diagnostics, and digital health, have expanded the capabilities and accessibility of IVDs, making them essential for both clinical and home-based settings. The rising prevalence of chronic diseases, infectious diseases, and the aging population further boosts the demand for IVD devices to monitor and manage these conditions effectively. Furthermore, the COVID-19 pandemic has highlighted the importance of IVDs, especially in rapid diagnostics and pandemic control, which has accelerated growth in this sector.

For procurement, the personalized medicine driver has a specific consequence: companion diagnostics. A growing share of oncology therapies requires a matched IVD test to identify eligible patients. This creates a bundled purchasing dynamic in which the pharmaceutical company’s label effectively specifies the diagnostic platform. A hospital that purchases a drug without access to the companion diagnostic cannot use the therapy. The procurement question is not “which IVD platform is most cost-effective” but “which platform is required by the therapeutic protocols this institution has adopted.” This is a form of supplier lock-in that is driven by clinical practice rather than commercial negotiation.

Market Challenges: Regulatory Fragmentation and Reimbursement Uncertainty
Despite the growth prospects, the IVD market faces significant challenges, primarily around regulatory hurdles and reimbursement issues. The regulatory environment for IVDs is complex and varies across regions, which can delay market entry and increase the cost of development. In addition, maintaining compliance with stringent quality standards, such as ISO certifications, requires significant investment in research and development. Furthermore, reimbursement for IVD tests can be inconsistent, especially for newer technologies or tests that are not widely adopted, which poses financial challenges for manufacturers. Additionally, the market faces intense competition, with numerous companies vying for market share, and the rapid pace of technological advancement means companies must continuously innovate to stay relevant.

The reimbursement challenge deserves procurement-specific attention because it determines whether a test is economically viable for the laboratory that adopts it. In the United States, Medicare payment rates for clinical laboratory tests are set under the Clinical Laboratory Fee Schedule, and newer molecular tests often face coverage determinations that vary by regional Medicare Administrative Contractor. A test that is clinically superior but unreimbursed is a cost center, not a revenue generator, for a hospital laboratory. In China, the National Healthcare Security Administration’s centralized volume-based procurement program has driven significant price reductions in chemical luminescence immunoassays, compressing margins for both domestic and multinational suppliers. Siemens Healthineers reported a low double-digit revenue decline in China attributable to centralized volume-based procurement, alongside a broader Diagnostics segment revenue of just under €1.1 billion in Q4, flat on a comparable basis . For buyers, the implication is that supplier pricing behavior varies dramatically by geography and product category. A supplier facing margin compression in China may seek to recover profitability in less price-sensitive markets, while a supplier with limited China exposure may offer more competitive terms elsewhere.

Product Segmentation: Immuno Diagnostics at 26.4% and the Automation Imperative
Immuno Diagnostics is the largest segment, holding a share of 26.4%.

Immunoassays—including enzyme-linked immunosorbent assays, chemiluminescence immunoassays, and lateral flow formats—dominate clinical laboratory testing volume because they cover the highest-throughput diagnostic categories: thyroid function, cardiac markers, tumor markers, infectious disease serology, and hormone panels. The procurement dynamics in this segment are shaped by automation. A high-volume hospital core lab requires a fully automated immunoassay platform with random-access capability, onboard reagent storage, and bidirectional laboratory information system connectivity. The switching cost for such a platform is substantial: method validation, reference range establishment, staff training, and interface development can consume six to twelve months.

Roche’s 2025 diagnostic portfolio activity illustrates the direction of competitive pressure. The company introduced two instrument platforms, six digital solutions, and 53 new tests in 2025, including a cobas Mass Spec solution with the industry’s broadest automated mass spectrometry IVD menu at 39 tests for therapeutic drug monitoring and steroid hormones . For procurement, the message is that the leading suppliers are expanding menu breadth as a lock-in mechanism. A platform with a broader test menu reduces the need for send-out testing to reference laboratories, which is operationally convenient for the lab but deepens dependency on the platform vendor. A buyer evaluating immunoassay platforms should assess not only current test menu coverage but the supplier’s pipeline for tests the institution is likely to need in three to five years.

Application Concentration: Hospitals at 57.6% and the Distributed Buying Problem
Hospital is the largest application segment, holding a share of 57.6%.

The hospital dominance means that the IVD market’s procurement dynamics are shaped by institutional buying processes rather than individual physician preference. But “hospital procurement” is not a monolithic category. In large academic medical centers, laboratory medicine departments may operate with substantial autonomy and negotiate directly with vendors. In smaller community hospitals, purchasing decisions may be consolidated through group purchasing organizations that negotiate on behalf of hundreds of facilities. In integrated delivery networks, standardization across sites is a stated goal but rarely achieved in practice because legacy platforms differ and conversion costs are high.

For suppliers, the 57.6% hospital share means that winning a platform placement in a major hospital system can anchor revenue for years. For buyers, it means that leverage varies with institutional size and purchasing sophistication. A small hospital negotiating alone has limited leverage against a Roche or Siemens. A hospital system that aggregates laboratory spend across a dozen facilities can negotiate service contracts, reagent pricing, and upgrade terms that are unavailable to individual buyers. The procurement action is to assess whether the institution’s purchasing structure captures the available leverage. If it does not, the first step is organizational, not commercial.

Competitive Landscape: 51.0% Concentration and the Geography of Supplier Strength
According to QYResearch Top Players Research Center, the global key manufacturers of In Vitro Diagnostics Medical Device include Roche, Danaher, Abbott, Siemens Healthineers, Thermo Fisher Scientific, etc. In 2024, the global top five players had a share approximately 51.0% in terms of revenue.

The 51.0% concentration is meaningful but not extreme by medical device standards. It means that credible alternatives exist outside the top five, particularly in regional markets and specialized segments. The geography of supplier strength matters for procurement strategy. Roche’s Diagnostics Division reported CHF 13,847 million in 2025 sales, with CHF 7,614 million from Core Lab and CHF 2,527 million from Molecular Lab . Danaher’s Diagnostics segment reported approximately $8.9 billion** in 2025 net sales . Abbott’s Diagnostics revenue was **$8.937 billion in 2025, down from $9.341 billion in 2024 . Siemens Healthineers Diagnostics segment reported adjusted revenue of €4,347 million in fiscal 2025, with adjusted EBIT margin of 7.7% .

For buyers, the financial performance of these suppliers is not academic. A supplier with declining diagnostics revenue and a stated transformation program—as Siemens has disclosed—is a supplier under pressure to restructure its cost base, which may affect service levels, product support, or willingness to offer favorable contract terms. A supplier with growing menu breadth and stable revenue—as Roche has reported—has less incentive to compete on price. The procurement implication is that supplier financial health and strategic priorities should be part of the qualification assessment, not just product specifications and pricing.

The Buyer’s Action List
The IVD medical device market’s structure—51.0% concentration, 57.6% hospital dominance, 26.4% immuno diagnostics share—describes a market where the most important procurement decisions are made before the purchase order. Three actions follow.

First, qualify on reimbursement viability, not just analytical performance. A test that is not reimbursed at a rate that covers the laboratory’s cost is a clinical tool with a negative economic value. Ask suppliers for reimbursement history by payer and jurisdiction, and for their strategy to obtain coverage for new tests. A supplier that cannot articulate a reimbursement pathway is selling a product that the laboratory may not be able to afford to use.

Second, evaluate menu breadth as a lock-in risk, not just a convenience. A broad menu reduces send-out testing, which is operationally attractive. But it also deepens dependency. For critical tests, identify whether a second platform is available within the institution or through a reference laboratory arrangement, and what the turnaround time and cost implications of that backup would be.

Third, map supplier geographic exposure against your own. A supplier with heavy China exposure may face margin pressure that affects global pricing. A supplier with limited China exposure may be more aggressive in other markets. Understanding the supplier’s financial geography helps predict where they will compete on price and where they will defend margin.

The IVD market rewards buyers who understand that the test is not the product; the reimbursement pathway and the platform ecosystem are. The 51.0% concentration, the 57.6% hospital share, and the 26.4% immuno diagnostics dominance are not abstractions. They describe a market where the cost of a wrong decision is measured in un reimbursed tests, stranded platform investments, and laboratory workflows that cannot adapt when a supplier’s strategic priorities shift.

Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp